Priority Lists
Protocol Posting of
Activations
Activation
A Phase II Study of Local Excision Alone or Local Excision Plus Adjuvant Chemoradiation Therapy for Small Distal Rectal Cancers
| Study Coordinator(s) | Morton S. Kahlenberg, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists, Surgeons |
Activation
Phase III Comparison of Catheter Based Therapy of Pleural Effusions in Cancer Patients (Optimal Pleural Effusion Control, OPEC)
| Study Coordinator(s) | Cynthia Jumper, M.D. |
| Participants | CTSU |
Activation
Phase III Intergroup Trial of Adjuvant Chemoradiation after Resection of Gastric or Gastroesophageal Adenocarcinoma
| Study Coordinator(s) | Tomislav Dragovich, M.D., Ph.D |
| Participants | CTSU |
Activation
A Phase III Study of Regional Radiation Therapy in Early Breast Cancer
| Study Coordinator(s) | Lori J. Pierce, M.D. |
| Participants | CTSU |
Partial Reactivation
A Phase II Study of OSI-774 (NSC #718781) in Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction
| Study Coordinator(s) | Tomislav Dragovich, M.D., Ph.D, James L. Abbruzzese, M.D. |
| Participants | Members, NCORP |
Closures
Permanent Closure
S0112, A Phase II Study Of Daunomycin And Ara-C, Both Given By Continuous IV Infusion For Previously Untreated Non-M3 Acute Myeloid Leukemia (AML) In Patients Of Age 56 Or Older.
| Study Coordinator(s) | Thomas R. Chauncey, M.D.,Ph.D., Alan F. List, M.D., David R. Head, M.D., Cheryl L. Willman, M.D., Marilyn L. Slovak, Ph.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists |
| Closure Date | 2003-04-01 |
Permanent Closure
A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) In Patients with Malignant Pleural Mesothelioma
| Study Coordinator(s) | Linda L. Garland, M.D., Michael Lobell, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
| Closure Date | 2003-04-01 |
Amendments, Revisions, Memoranda
Memorandum
A Randomized Double-Blinded Trial of Estrogen Replacement Therapy Versus Placebo in Women With Stage I or II Endometrial Adenocarcinoma
| Participants | Members, NCORP, Surgeons, Pathologists |
Revision #1
Phase II Trial of Surgery with Perioperative INGN 201 (Ad5CMV-p53) Gene Therapy Followed by Chemoradiotherapy for Advanced, Resectable Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx and Larynx
| Study Coordinator(s) | George Yoo, M.D., S.G. Urba, M.D., Harold Kim, M.D., Ehab Hanna, M.D. |
| Participants | Limited: Institutions Listed on the Title Page |
Memorandum
"Phase III Randomized, Intergroup Trial Assessing the Clinical Activity of STI-571 at Two Dose Levels in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the KIT Receptor Tyrosine Kinase (CD117)"
| Study Coordinator(s) | George Demetri, M.D., Christopher Fletcher, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Surgeons, Pathologists, CALGB, ECOG, NCIC-CTG |
Memorandum
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Every 21 Days in Patients With Advanced Pancreas Cancer
| Study Coordinator(s) | Robert P. Whitehead, M.D. |
| Participants | Members, NCORP |
Revision #4
A Phase II Trial of a D1/3-MAGE-3-His Fusion Protein (NSC-719274) with Adjuvant SB-AS02B (NSC-719275) for Patients with Selected Stage IV, M1a or M1b Metastatic Melanoma
| Study Coordinator(s) | Jeffrey S. Weber, M.D., Vernon K. Sondak, M.D., Mary L. Disis, M.D. |
| Participants | Limited: Institutions Listed on the Title Page |
Amendment #1
Randomized Phase III Trial of Cisplatin and Irinotecan versus Cisplatin and Etoposide in Patients with Extensive Stage Small Cell Lung Cancer
| Study Coordinator(s) | Ronald B. Natale, M.D., David R. Gandara, M.D., Primo N. Lara, Jr., M.D., Heinz- Josef Lenz, M.D. |
| Participants | Members, NCORP, Affiliates, Medical Oncologists, Pathologists, CTSU |
Memorandum
A Phase II Study of Oral EGFR Tyrosine Kinase Inhibitor OSI-774 (NSC-718781) In Patients with Malignant Pleural Mesothelioma
| Study Coordinator(s) | Linda L. Garland, M.D., Michael Lobell, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Memorandum
Lung Cancer Specimen Repository Protocol, Ancillary
| Study Coordinator(s) | Wilbur A. Franklin, M.D., Paul H. Gumerlock, Ph.D., David R. Gandara, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, NCIC-CTG, ECOG |
Revision #4 (Revised)
Lung Cancer Specimen Repository Protocol, Ancillary
| Study Coordinator(s) | Wilbur A. Franklin, M.D., Paul H. Gumerlock, Ph.D., David R. Gandara, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, NCIC-CTG, ECOG |
Amendment #1
Gastrointestinal Tumor Repository Protocol, Ancillary
| Study Coordinator(s) | Cecilia M. Fenoglio-Preiser, M.D., Grant N. Stemmermann, M.D., Amy E. Noffsinger, M.D., Paul E. Hurtubise, M.D. |
| Participants | Members, Pathologists, NCORP |
Revision #5
Gastrointestinal Tumor Repository Protocol, Ancillary
| Study Coordinator(s) | Cecilia M. Fenoglio-Preiser, M.D., Grant N. Stemmermann, M.D., Amy E. Noffsinger, M.D., Paul E. Hurtubise, M.D. |
| Participants | Members, Pathologists, NCORP |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required